Quidel enlisted ICS' multidisciplinary team to be the application developer of the next-generation, fully integrated molecular diagnostic system for its Savanna platform.
The low-cost, point-of-care testing platform allows for easy rapid results for disease states and conditions such as COVID-19, MRSA and HIV.
The Savanna project started with UX design leading to an intuitive CLIA-waived touchscreen interface and an extensible processing architecture. It also includes software applications and powerful, forward-looking cybersecurity for its fleet in the field.
With Savanna, Quidel will deploy a future-proof in-vitro diagnostics platform that's flexible, scalable, configurable and secure.
In its collaboration with ICS, Quidel convenes best-practices from usability, cybersecurity, cloud and user management on an embedded touch-screen platform.
ICS has collaborated with Quidel on other point-of-care technologies, which have received Emergency Use Authorization from the US Food and Drug Administration.
ICS assisted Quidel in bringing development in-house, setting up a new continuous integration system to build the software and run automated unit tests, enabling the generation of new software releases following a development and test process that meets the stringent requirements of medical devices.
ICS also designed and implemented new product features, including an IoT-based facility for software updates and remote device management.
At the intersection of custom software development, engineering and UX design, Integrated Computer Solutions (ICS) has been helping Fortune 1000 companies create transformative products for over 30 years.
ICS is headquartered in Waltham, Mass., with offices in Sunnyvale, California and Ottawa, Ontario.
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older